Multiple randomized studies have demonstrated improved response rates, progression-free survival, and quality of life for treatment-naive, advanced-stage adenocarcinoma patients harboring sensitizing EGFR mutations when they are treated with tyrosine kinase inhibitor therapy, as compared with chemotherapy. Despite improved outcomes with these agents, the majority of patients will eventually develop resistance and subsequent clinical progression. Recently, there has been a firmer understanding of the molecular mechanisms of the resistance that develops as a consequence of treatment, most notably the identification of a second-site EGFR mutation, T790M. While this understanding can inform subsequent treatment decisions, disease progression can be heterogeneous, and there are several competing therapeutic options. Treatment decisions must consider this clinical heterogeneity, factoring in the pace of disease growth, lung cancer–related symptoms, and the potential presence of T790M mutations. Herein, we review the available literature addressing these competing strategies and attempt to clarify best treatment practices, including the emerging role of T790M-directed therapies.
目前分類:肺腺癌 (6)
- Oct 07 Fri 2016 08:37
攻擊一個移動的目標: 瞭解和管理EGFR肺腺癌對TKI標靶藥品的抗藥性
- Jul 31 Sun 2016 10:41
細懸浮微粒PM2.5 女性肺癌殺手
- Jul 31 Sun 2016 10:38
肺癌危險因子
高雄醫學大學研究發現,罹患肺癌的危險因子除了吸菸之外,肺結核患者、炒菜未使用抽油煙機及居住鄰近工業區的人都較易罹患肺癌,且吸菸者本身罹患鱗狀細胞或小細胞肺癌的機率高,吸二手菸者及油煙則較易罹患肺腺癌。
- Jul 31 Sun 2016 10:28
肺腺癌增加之可能原因
- Jul 31 Sun 2016 10:20
柴油燃燒的廢氣會增加肺癌的風險及死亡率